Remove tag new-medicines
article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Kesselheim, a professor of medicine at Harvard Medical School via the Washington Post , says “the worst thing for people with Alzheimer’s would be to put out a product that doesn’t work.” After the CEO departed the sinking ship, new management pinned all their hopes on the Biogen drug for Alzheimer’s.

article thumbnail

What is Biogen and can they repair their reputation?

World of DTC Marketing

This drug was never about patients; it was about a company whose ego got too big and needed a savior in the form of a medicine that could bring in hundreds of millions of dollars. I remember when Biogen was an exciting new biotech based in Westin. They had a new MS drug that was the talk of the industry and an exciting pipeline.

Insurance 222
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

J&J gets first approval for multiple myeloma bispecific Tecvayli

pharmaphorum

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

FDA 91
article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

million price tag. But the justification for Roctavian’s cost will depend on positive responses to the treatment, says Dr. Guy Young, professor of pediatrics at University of Southern California’s Keck School of Medicine. The post Can gene therapies for haemophilia defend their high price tags? million ($1.8

Safety 111
article thumbnail

CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision

pharmaphorum

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer.